Pioglitazone Inovamed

/ Inovamed

See prescribing information for full details

Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below: as monotherapy – in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination with – metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.- Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.

*Hypersensitivity to the active substance or to any of the excipients
*Cardiac failure or history of cardiac failure
*Hepatic impairment
*Diabetic ketoacidosis
*Current bladder cancer or a history of bladder cancer
*Uninvestigated macroscopic haematuria

See prescribing information for full details

See prescribing information for full details

See prescribing information for full details

See prescribing information for full details

See prescribing information for full details